期刊
CURRENT DRUG TARGETS
卷 19, 期 8, 页码 927-937出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450118666170328122527
关键词
Cholinesterase inhibitors; curcumin; epigallocatechin-3-gallate; N-methyl-D-aspartate; neurodegenerative disease; polyphenolic compounds; resveratrol
资金
- Ministry of Agriculture via NKEA Research Grant Scheme (NRGS) [NH1014D034]
- Universiti Kebangsaan Malaysia via NKEA Research Grant Scheme (NRGS) [NH1014D034]
- Agro-Based Industry Malaysia via NKEA Research Grant Scheme (NRGS) [NH1014D034]
Neurodegenerative disease is an incurable disease which involves the degeneration or death of the nerve cells. Alzheimer's Disease (AD) is a neurodegenerative disease discovered in 1906 by Alois Alzheimer, a German clinical psychiatrist and neuroanatomist. The main pathological hallmarks of this disease are the formation of extracellular amyloid beta (A beta) plaques and intracellular neurofibrillary tangle (NFT). The accumulation of the amyloid protein aggregates in the brain of AD patients leads to oxidative stress and inflammation. Other postulated reasons for the development of this disease are cholinergic depletion and excessive glutamatergic neurotransmission. The current drugs approved and marketed for the treatment of AD are cholinesterase inhibitors (ChEIs) and N-methyl-Daspartate (NMDA) receptor antagonists. The function of ChEIs is to avoid cholinergic depletion; whereas the function of NMDA receptor antagonist is to block excessive glutamatergic neurotransmission. Unfortunately, the current drugs prescribed for AD show only modest improvement in terms of symptomatic relief and delay the progression of the disease. This review will discuss about several polyphenolic compounds as potential natural treatment options for AD. Three compounds are highlighted in this review - Curcumin (Cur), Resveratrol (Rsv) and Epigallocatechin-3-gallate (EGCG). These compounds have huge potential for AD treatment, especially due to their low frequency of adverse events. However, the current conventional pharmaceutical drugs remain as the mainstay of treatment for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据